Unknown

Dataset Information

0

Radiomics-based prediction of HCC response to atezolizumab/bevacizumab

ABSTRACT:

SUBMITTER: Rodriguez I 

PROVIDER: S-EPMC12373426 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Unraveling the immune-activated tumor microenvironment correlated with clinical response to atezolizumab plus bevacizumab in advanced HCC.
| S-EPMC11929055 | biostudies-literature
Unknown Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.
| S-EPMC11999108 | biostudies-literature
Unknown Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
| S-EPMC8452577 | biostudies-literature
Unknown Ultrasounic-radiomics models for predicting the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma.
| S-EPMC12571321 | biostudies-literature
Unknown Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab.
| S-EPMC11773230 | biostudies-literature
Transcriptomics Prediction of response to bevacizumab
2013-01-03 | GSE19862 | GEO
Transcriptomics Prediction of response to bevacizumab
2013-01-03 | E-GEOD-19862 | biostudies-arrayexpress
Unknown Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
| S-EPMC10267515 | biostudies-literature
Unknown Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study.
| S-EPMC12742031 | biostudies-literature
Unknown Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.
| S-EPMC11889551 | biostudies-literature